Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court
Good News For Gene Therapy Continues As FDA Also Removes Hold On Voyager’s Huntington’s Trial
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
You may also be interested in...
The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.
There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.